TY - JOUR
T1 - Prospective study of endogenous circulating estradiol and risk of stroke in older women
AU - Lee, Jennifer S.
AU - Yaffe, Kristine
AU - Lui, Li Yung
AU - Cauley, Jane
AU - Taylor, Brent
AU - Browner, Warren
AU - Cummings, Steven
PY - 2010/2
Y1 - 2010/2
N2 - Objective: To test the hypothesis that circulating endogenous estradiol is associated with stroke risk in older postmenopausal women. Stroke incidence increases after menopause, when endogenous estrogen levels fall, yet exogenous estrogen increases strokes in older postmenopausal women. The relation between endogenous estrogen and stroke is unclear. Design: Prospective case-control study. Setting: Study of Osteoporotic Fractures. Patients or Other Participants: Women at least age 65 years (99% follow-up) who were not taking estrogen at baseline. Main Outcome Measures: Free estradiol index (FEI) was calculated by dividing total estradiol by sex hormone-binding globulin concentrations measured in banked baseline serum. Using logistic regression, odds ratios were estimated for a first-ever atherothrombotic stroke associated with endogenous FEI in 196 women who had a subsequent validated stroke (median follow-up, 8 years) compared with 219 randomly selected women who did not. Potential mediators were assessed in multivariable models. Results: The age-adjusted odds of atherothrombotic stroke increased with increasing FEI quartiles (Ptrend=.007). Women in the highest FEI quartile had an age-adjusted 2.31-fold (odds ratio, 2.31; 95% confidence interval, 1.28-4.17) higher odds than women in the lowest quartile. Women with greater central adiposity had a suggestively stronger association (P=.08). Atherogenic dyslipidemia, type 2 diabetes mellitus, and C-reactive protein level were potential mediators of this relation. Conclusions: Endogenous estradiol level is an indicator of stroke risk in older postmenopausal women, especially in those with greater central adiposity. Potential mediators, including atherogenic dyslipidemia, insulin resistance, and inflammation, might underlie this association. Whether estradiol, independent of atherogenic adiposity, influences such mediators and stroke risk needs to be determined. Estrogen-altering agents might be harmful or beneficial depending on endogenous estradiol levels, especially in women with greater central adiposity.
AB - Objective: To test the hypothesis that circulating endogenous estradiol is associated with stroke risk in older postmenopausal women. Stroke incidence increases after menopause, when endogenous estrogen levels fall, yet exogenous estrogen increases strokes in older postmenopausal women. The relation between endogenous estrogen and stroke is unclear. Design: Prospective case-control study. Setting: Study of Osteoporotic Fractures. Patients or Other Participants: Women at least age 65 years (99% follow-up) who were not taking estrogen at baseline. Main Outcome Measures: Free estradiol index (FEI) was calculated by dividing total estradiol by sex hormone-binding globulin concentrations measured in banked baseline serum. Using logistic regression, odds ratios were estimated for a first-ever atherothrombotic stroke associated with endogenous FEI in 196 women who had a subsequent validated stroke (median follow-up, 8 years) compared with 219 randomly selected women who did not. Potential mediators were assessed in multivariable models. Results: The age-adjusted odds of atherothrombotic stroke increased with increasing FEI quartiles (Ptrend=.007). Women in the highest FEI quartile had an age-adjusted 2.31-fold (odds ratio, 2.31; 95% confidence interval, 1.28-4.17) higher odds than women in the lowest quartile. Women with greater central adiposity had a suggestively stronger association (P=.08). Atherogenic dyslipidemia, type 2 diabetes mellitus, and C-reactive protein level were potential mediators of this relation. Conclusions: Endogenous estradiol level is an indicator of stroke risk in older postmenopausal women, especially in those with greater central adiposity. Potential mediators, including atherogenic dyslipidemia, insulin resistance, and inflammation, might underlie this association. Whether estradiol, independent of atherogenic adiposity, influences such mediators and stroke risk needs to be determined. Estrogen-altering agents might be harmful or beneficial depending on endogenous estradiol levels, especially in women with greater central adiposity.
UR - http://www.scopus.com/inward/record.url?scp=76149125767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76149125767&partnerID=8YFLogxK
U2 - 10.1001/archneurol.2009.322
DO - 10.1001/archneurol.2009.322
M3 - Article
C2 - 20142527
AN - SCOPUS:76149125767
SN - 0003-9942
VL - 67
SP - 195
EP - 201
JO - Archives of Neurology
JF - Archives of Neurology
IS - 2
ER -